Novo Nordisk invests USD 2.6bn in new manufacturing facilities

The pharmaceutical company plans to build three new manufacturing facilities and to expand one factory in the Danish city of Kalundborg. Construction is anticipated to create around 400 new jobs.

Photo: Novo Nordisk / PR

With an investment of DKK 17bn (USD 2.6bn), Novo Nordisk seeks to strengthen all of the links in its global value chain, from drug production to packaging, it announces in a press release on Monday.

The sum will be spent on three new manufacturing facilities plus an expansion of its existing facility in Kalundborg, Denmark, with the goal of establishing additional capacity for the production of active pharmaceutical ingredients (APIs).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs